Graft vs. host disease and graft vs. myeloma effect after non-myeloablative allogeneic transplantation

Leukemia & Lymphoma
J A Pérez-SimónJesús San Miguel

Abstract

For many years progress in event free and overall survival in patients diagnosed with multiple myeloma have been modest, however recently newer therapeutic options have become available and, for a small but increasing subset of patients, an "operational cure" can be offered. Although autologous transplantation is associated with a prolongation in event free and overall survival as compared to conventional chemotherapy, there is no plateau in the survival curves. By contrast, the use of allogeneic hematopoietic stem cells provides a tumor-free stem cell source and graft-vs.-myeloma activity leading to a higher frequency of long term survivors in molecular remission. Unfortunately, allogeneic transplantation has been associated with high transplant-related mortality (TRM). Non-myeloablative or reduced intensity conditioning (RIC) regimens, designed to be immunosuppressive rather than myeloablative, in an effort to reduce the toxicity and TRM associated with high dose chemotherapy, but maintaining the GVM effect, have been developed showing up to 90% overall response rate and low TRM. Interestingly, in a significant proportion of patients disease response is preceded by GVHD, suggesting a clear relationship between GVHD and graft ...Continue Reading

References

Feb 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W M GregoryJ S Malpas
Jun 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G GahrtonP Jacobs
Mar 23, 1996·Lancet·L F VerdonckE J Petersen
Jul 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J BladéE Montserrat
Nov 25, 1998·Bone Marrow Transplantation·J Mehta, S Singhal
Jun 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G MartinelliM Cavo
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M LokhorstL F Verdonck
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ashraf BadrosGuido Tricot
Mar 29, 2002·The Hematology Journal : the Official Journal of the European Haematology Association·J BladéE Montserrat
Jan 25, 2003·British Journal of Haematology·Juan José LahuertaUNKNOWN Grupo Español de Síndromes Linfoproliferativos/Trasplante Autólogo de Médula Osea
Apr 26, 2003·Blood·Toshiaki HayashiKenneth C Anderson
May 9, 2003·The New England Journal of Medicine·J Anthony ChildUNKNOWN Medical Research Council Adult Leukaemia Working Party
Jun 27, 2003·The New England Journal of Medicine·Paul G RichardsonKenneth C Anderson
Dec 26, 2003·The New England Journal of Medicine·Michel AttalUNKNOWN InterGroupe Francophone du Myélome

❮ Previous
Next ❯

Citations

Dec 7, 2013·Best Practice & Research. Clinical Haematology·Anthony D Sung, Nelson J Chao
Dec 17, 2008·Bone Marrow Transplantation·G CookD I Marks
Sep 30, 2005·European Journal of Haematology·Evangelos TerposJane F Apperley
Jun 17, 2005·Expert Opinion on Pharmacotherapy·Evangelos TerposMeletios-Athanassios Dimopoulos
Apr 4, 2009·Physiological Reviews·Michael J Tisdale

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

© 2022 Meta ULC. All rights reserved